January 12, 2018
Pfizer Inc. is recalling 30-count bottles of 25-mg Zoloft (sertraline hydrochloride) tablets (NDC 0049-4960-30), according to the January 10, 2018, US Food and Drug Administration (FDA) Enforcement Report. The company cited weight variations in the tablets that have caused superpotent and subpotent drugs.
The recall affects 1972 bottles of Zoloft from lot S84026. The bottles were distributed across the United States by Pfizer’s Roerig division.
Pfizer voluntarily initiated the recall October 20, 2017. On January 4, 2018, the FDA designated it Class II, signaling use of the prescription drug could cause temporary, reversible adverse effects with a remote likelihood of serious harm.
Zoloft is a selective serotonin reuptake inhibitor used in the treatment of depression, obsessive-compulsive disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, social anxiety disorder, and panic disorder.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here